Evidence map›Paper›PMID 38599819›Full record

Trial reportMaternal & child nutrition2024

Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA).

Muriel Vray, Laura Tondeur, Boris G Hedible, Rindra Vatosoa Randremanana, Alexandre Manirakiza, Ramatoulaye Hamidou Lazoumar, Cassandre Van Platen, Antonio Vargas, André Briend, Ronan Jambou and 1 more

Abstract readRandomized Controlled TrialPragmatic Clinical TrialMulticenter Study
In one paragraph

Trial report in Maternal & child nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muriel VrayEmerging Diseases Epidemiology Unit, Institut de Pasteur, Université Paris-Cité, Paris, France.ORCID 0000-0002-3559-6532
Laura TondeurEmerging Diseases Epidemiology Unit, Institut de Pasteur, Université Paris-Cité, Paris, France.
Boris G HedibleCERPOP UMR1295 Inserm, University of Toulouse, Toulouse, France.
Rindra Vatosoa RandremananaEpidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.ORCID 0000-0002-6174-8827
Alexandre ManirakizaEpidemiology and Clinical Research Unit, Institut Pasteur de Bangui, Bangui, Central African Republic.
Ramatoulaye Hamidou LazoumarUnit of Epidemiology-Health-Environment-Climate, Centre de Recherche Médicale et Sanitaire (CERMES), Niamey, Niger.
Cassandre Van PlatenCenter for Translational Science, Clinical Core, Institut Pasteur, Paris, France.
Antonio VargasNutrition and Health Unit, Action Against Hunger, Madrid, Spain.
André BriendDepartment of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg, Denmark.
Ronan JambouDirection Scientifique, Centre de Recherche Médicale et Sanitaire (CERMES), Niamey, Niger.
Malinea Clinical Trial Group

Funding

Action Contre La FaimMinistère de l'Europe et des Affaires Étrangères
6 · The paper itself

Abstract

The main objective of this project was to compare in the field conditions two strategies of re-nutrition of children with moderate acute malnutrition (MAM) aged from 6 to 24 months, targeting the microbiota in comparison with a standard regimen. A three-arm, open-label, pragmatic randomised trial was conducted in four countries (Niger, CAR, Senegal and Madagascar). Children received for 12 weeks either fortified blended flour (FBF control) = arm 1, or FBF + azithromycin (oral suspension of 20 mg/kg/day daily given with a syringe) for the first 3 days at inclusion = arm 2 or mix FBF with inulin/fructo-oligosaccharides (6 g/day if age ≥12 months and 4 g if age <12 months) = arm 3. For each arm, children aged from 6 to 11 months received 100 g x 2 per day of flours and those aged from 12 to 24 months received 100 g × 3 per day of FBF. The primary endpoint was nutritional recovery, defined by reaching a weight-for-height z-score (WHZ) ≥ -1.5 within 12 weeks. Overall, 881 children were randomised (297, 290 and 294 in arm 1, arm 2 and arm 3, respectively). Three hundred and forty-four children were males (39%) and median/mean age were 14.6/14.4 months (SD = 4.9, IQR = 10.5-18.4). At inclusion, the three arms were comparable for all criteria, but differences were observed between countries. Overall, 44% (390/881) of the children recovered at week 12 from MAM, with no significant difference between the three arms (41.4%, 45.5% and 45.9%, in arm 1, arm 2 and arm 3, respectively, p = 0.47). This study did not support the true advantages of adding a prebiotic or antibiotic to flour. When using a threshold of WHZ ≥ -2 as an exploratory endpoint, significant differences were observed between the three arms, with higher success rates in arms with antibiotics or prebiotics compared to the control arm (66.9%, 66.0% and 55.2%, respectively, p = 0.005).

Indexed as

FlourFood, FortifiedGastrointestinal MicrobiomeAnti-Bacterial AgentsAzithromycinChild, PreschoolFemaleHumansInfantInulinMaleOligosaccharidesPrebioticsAnti-Bacterial AgentsAzithromycinInulinOligosaccharidesPrebioticsCentral African RepublicMadagascarmalnutritionmicrobiotaNigerprebioticSenegal

Identifiers

PMID38599819
PMCPMC11168351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.